anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
PURPOSE:To obtain a hypotensive retaining agent, comprising diadenosine 5&#39;,5&#39;&#39;&#39;- p&lt;1&gt;,p&lt;4&gt;-tetraphosphate (Ap4A) as an active ingredient, excellent in regulating properties for blood pressure and having high safety. CONSTITUTION:The objective hypotensive retaining agent comprises an effective amount of Ap4A, having vasodilator action and expressed by the formula or its pharmaceutically permissible salt as an active ingredient. The effective amount is usually an amount enabling the induction of the hypotensive retaining action in hypotensive anesthesia in a human or other mammals so as to reduce the average arterial pressure to usually &lt;50%, preferably &lt;=40% before administering the medicine. This compound is capable of rapidly reducing the blood pressure from the start of the administration, retaining the objective blood pressure and quickly recovering the blood pressure by discontinuing the administration. The hypotensive retaining action in the anesthesia is not affected by a difference in an anesthetic agent. Furthermore, the bloodstream in the heart and brain is increased by this agent in a hypotensive amount with no undesired influence on the heart (reduction and change in heart rate) and causing acidosis or reduction in gas partial pressure in the blood.
PURPOSE:To obtain an antihypertensive agent free from side effects, containing an extract which has association relationship to organisms, high safety and is prepared by extracting a cell of bacterium belonging to the genus Streptococcus or Enterococcus with water. CONSTITUTION:A cell of bacterium belonging to the genus Streptococcus or Enterococcus is extracted with warm water at &gt;=50 deg.C and the cell is removed after the extraction to give an extracted solution. The extracted solution is concentrated and dried as it is and used as an antihypertensive agent. Further preferably salts and other low-molecular substances are removed from the extracted solution by dialysis, etc., to give a more effective antihypertensive agent. The extract of cell or the antihypertensive agent has no toxicity at all or extremely low toxicity. The antihypertensive agent can be administered orally and by injection. The antihypertensive agent has intermediate effects, durable effects and is inexpensive. The antihypertensive agent is not only used as a drug but also is added to foods and usable for preventing and treating hypertension.
NEW MATERIAL:A compound of formula I (R is H or OH, the wavy line represents the carbon atoms at the 24-position to be in the R- or S- configuration or a mixture of the R- with S-configurations). EXAMPLE:24(R)-25-Dehydro-1alpha,24-dihydroxyvitamin D3. USE:A calcium regulating agent useful as a remedy for osteopathy, e.g. osteoporosis or osteomalacia, etc. due to the abnormal calcium metabolism. PREPARATION:24-Oxo-25-dehydrovitamin D3 of formula II (R&lt;1&gt; is H, OH or protected OH; R&lt;2&gt; is H or a protecting group) is reduced with a boron hydride compound, e.g. sodium boron hydride, in an organic solvent at 5-50 deg.C, and if necessary the protecting group is removed from the hydroxyl group to afford the aimed compound of formula I .
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a carbonated spring generation method and device for efficiently generating a high concentration carbonated spring.  &lt;P&gt;SOLUTION: To a pressure container 1, a pressurized carbon dioxide is supplied. Hot water from a bathtub 4 is continuously supplied through a raw water pumping pipe 5 into the pressure container 1, scattered in the gaseous phase area of the pressure container 1, brought into contact with the carbon dioxide in the state of water particles, turned to the carbonated spring containing the carbon dioxide, and stored at the bottom of the pressure container 1 as a liquid phase. The carbonated spring inside the pressure container 1 is continuously discharged through a carbonated spring discharge pipe 7 to the bathtub 4. A discharge amount suppressing mechanism 8 such as an orifice is interposed in a carbonated spring discharge pipe 406 and thus the state of storing the carbonated spring at a prescribed water level at the bottom of the pressure container 1 is maintained.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
PCT No. PCT/US95/14018 Sec. 371 Date Aug. 25, 1997 Sec. 102(e) Date Aug. 25, 1997 PCT Filed Oct. 27, 1995 PCT Pub. No. WO96/13598 PCT Pub. Date May 9, 1996The present invention provides a hybrid vector construct which comprises a portion of an adenovirus, 5&#39; and 3&#39;ITR sequences from an AAV, and a selected transgene. Also provided is a hybrid virus linked via a polycation conjugate to an AAV rep gene to form a single particle. These trans-infection particles are characterized by high titer transgene delivery to a host cell and the ability to stably integrate the transgene into the host cell chromosome. Also disclosed is the use of the hybrid vectors and viruses to produce large quantities of recombinant AAV.
PROBLEM TO BE SOLVED: To obtain the subject new compound capable of giving improved glass which is easily mixable with an aqueous polyacrylic acid solution, has high fluoride ion releasing ability and can afford cement with improved diameter tensile strength and fracture toughness. SOLUTION: This new compound is represented by formula I (R1 to R4 are each H, CH3, COOH or CH2COOH; R5 and R6 are each a bivalent alkylene; R7 is an alkyl; T1 and T2 are each H or an alkyl; w is 0-12; x, y and z are each &gt;=1), being obtained, for example, by reaction between an active hydrogen group-contg. ethylene-based unsaturated compound and an electrophilic group- bearing alkoxysilane; wherein the ethylene-based unsaturated compound is e.g. (meth)acrylic acid, maleic acid, itaconic acid; the alkoxysilane is pref. an isocyanato-functional alkoxysilane, specifically, e.g. isocyanatoethyltrimethoxysilane, isocyanatopropyltriethoxysilane.
2134675 9322430 PCTABS00027 The keratin K1 vector for expression of a nucleic acid cassette in the epidermis. The vector has a 5&#39; flanking region of the keratin K1 gene including a 5&#39; flanking sequence, a keratin K1 promoter, 5&#39; transcribed but untranslated region and a first intron and an intron/exon boundary, all in sequential and positional relationship for expression of a nucleic acid cassette. A 3&#39; flanking region in the K1 keratin gene containing regulatory sequences including a 3&#39; transcribed but untranslated region and contiguous noncoding DNA containing the transcriptional termination region. The 3&#39; flanking region and a 5&#39; flanking region are linked by a polylinker having a plurality of restriction endonuclease sites for the insertion of a nucleic acid cassette. The nucleic acid cassette encodes a sequence which can be used to express any protein, polypeptide or antisense RNA. The vector can be inserted both in vivo and ex vivo into epidermal cells. Further, it can be used for making transgenic animals or bioreactors of epidermal cells. The vector has been found useful for gene therapy in treatment of a variety of diseases including skin ulcers, wound healing, surgical incisions, psoriasis and cancer.
PROBLEM TO BE SOLVED: To obtain a new compound useful for the suppression of atherosclerosis and coronary heart diseases and capable of being utilized as an antiatheroselerotic medicine. SOLUTION: A benzyloxy-substituted penylglycinolamide of formula I (A is a four to eight-membered carbon ring, etc.; X is a single bond or a group of formula II; D and E are each H, a 3-8C cycloalkyl, etc.; R&lt;1&gt; is a 3-8C cycloalky, etc.; R&lt;2&gt; is H, a 4C alkyl, etc.; R&lt;3&gt; is H, CH2 OH; R&lt;4&gt; is hydroxy, a halogen, etc.) and its salt. The compound of formula I is obtained by activating the functional carboxyl group of a carboxylic acid of formula III and subsequently reacting the activated compound with a compound of formula IV in the presence of a base and/or an auxiliary agent in an inactive solvent (e.g. an ether compound) at a reaction temperature of 0-150 deg.C generally in the atmospheric pressure in a protecting gas atmosphere. The base used herein is usually an inorganic or organic base, and is used in an amount of 0.6-5 moles per mole of the compound of formula III.
A computerized method and system for notifying a consumer whether identified elements are contained in selected products. The system consist of at least one computer server and hand held computing device interconnected in a client server environment. A manufacturer registers their UPC&#39;s with the system. A consumer registers their elements (ie allergy information) with the system. Utilizing a scanner connected to the handheld computing device, the consumer scans in the UPC codes of the selected products. The system compares the ingredients of the selected products is compared with the consumer&#39;s allergies. The results of the comparison is displayed to the consumer.
PROBLEM TO BE SOLVED: To obtain the subject medicine having preventive and treating effects effective against all influenza viruses without relating to the antigenic variation of the viruses by including glucoproteins obtained from the cell membranes of avian erythrocytes. SOLUTION: Avian erythrocytes are separated from avian blood, hemolyzed in a 0.5% acetic acid solution, and subsequently centrifuged. The obtained cell membranes of the avian erythrocytes are subjected to an extraction method, a phenol distribution method, an ethanol precipitation method, a dialysis method, a lyophilization method, etc. The obtained glycoproteins contain a glycoprotein having a mol.wt. of &gt;=100,000 and a glycoprotein having a mol.wt. of &lt;=35,000, and contain sugar chains which are receptors capable of binding to influenza viruses. The glycoproteins are processed to obtain the objective influenza virus medicine containing the glycoproteins as active ingredients and not affected by the antigenic variation of the virus.
A system and method for predicting loss associated with a patient&#39;s use of a treatment device is disclosed. The communication interface collects event data related to the operation of the treatment device to deliver medication to the patient. Event data and clinical data of the patient are stored. The attrition analysis module inputs the event data and the clinical data and applies a machine learning model to determine a likelihood of attrition of the patient over a predetermined period of time based on the input event data and clinical data. The machine learning model is trained from a machine learning pipeline having event data and clinical data from a patient population using a treatment apparatus as inputs to determine at least one trigger for patient churn. It is determined whether the likelihood of churn exceeds a threshold. If the likelihood of loss exceeds a threshold, an action associated with the patient is triggered.
PURPOSE:To provide an antiserum containing an antibody against a specific mustard compound and capable of selectively destructing a cancer tissue. CONSTITUTION:The objective antiserum contains an antibody against the compound of formula I [R is alkyl or group of formula II - formula VII (Z is formyl or acetyl; R1, R3, R4, R6 and R7 are H or alkyl; R2 is alkyl, benzyl or alkoxycarbonyl; R5 is alkylene; n and n&#39; are 0-2)], e.g. N-[3-(p-[bis(2- chloroethyl)-amino]-phenyl)-N-formyl-DL-alan-yl]valine. The above compound is injected into a cancer tissue beforehand and said antiserum is administered to the patient to effect the antigen-antibody reaction in or near the cancer tissue to break the tissue. Cancer can be cured irrespective of the kind of the cancer without being influenced with a cancer antigen in blood. It is not necessary to determine the specific antigen of the cancer of the patient itself not taking consideration of the subcluster of the cancer cells.
PURPOSE:To obtain a hair dyeing agent having excellently dyeing properties free from stain on one&#39;s skin, dyeing the hair in light color tone, containing water-soluble dye, dyeing assistant ana an oxidizing agent, by adjusting pH of the dyeing agent to specific alkalinity. CONSTITUTION:A hair dyeing agent containing 0.001-10wt.% water-soluble dye, 1-30wt.% dyeing assistant and 1-30wt.% oxidizing agent (e.g. hydrogen peroxide). Besides these components, the hair dyeing agent is properly mixed with well-known compounding additives such as surfactant, thickening agent, ultraviolet light absorber and perfume, further blended with a pH adjuster such as ammonia water or ammonium sulfate and adjusted to pH7.5-11 to give the objective substance. The substance can be prepared into a form such as powder, aqueous solution, gel, paste, cream, aerosol and aerosol foam. Benzyl alcohol or N-methylpyrrolidone may be cited as the dyeing assistant.
The present invention relates to a medicament with an analgesic, antipyretic and/or antiinflammatory effect based on a salicylic acid derivative. The state of the art is always searching for alternatives to active ingredients such as acetylsalicylic acid (ASA) and ethenzamide in order to eliminate intolerance or to be able to offer simpler and better ingredients, which act as rapidly as possible, for a wide variety of possible administrations. Surprisingly, the invention has now succeeded in demonstrating that ethenzamide is very rapidly and completely metabolised in the human body to 2-Ethoxybenzoic acid. Ethenzamide is only a prodrug. It was possible to rule out metabolism to salicylamide. It was likewise possible to demonstrate the analgesic effect of 2-ethoxybenzoic acid. It correlates with the serum levels and persists for more than 8 hours. 2-Ethoxybenzoic acid is very rapidly absorbed. The serum maxima are reached after only 30 minutes; 2-ethoxybenzoic acid is still detectable in the serum even after 24 hours. These properties make 2-ethoxybenzoic acid an ideal analgesic which has a rapid onset of action and which has no effect on blood coagulation. Since the bioavailability is higher, it is also possible to reduce the single doses. By virtue of the physicochemical properties of 2-ethoxybenzoic acid, use in the form of a solution is possible so that, besides solid drug forms for oral and rectal use, it is also possible to prepare and use liquid formulations such as solutions for administration as drops or by injection. &lt;IMAGE&gt;
The application relates to the field of biomedicine, and particularly discloses a specific human lung cancer aptamer, a screening method and application thereof. The nucleic acid sequence of the aptamer is shown as SEQ ID NO. 1. The aptamer nucleic acid sequence can specifically recognize lung cancer serum by adopting a 5 &#39;end or 3&#39; end modification and marking method. Therefore, the method can be used for auxiliary diagnosis or targeted therapy of the lung cancer. The method is simple, rapid and sensitive, is suitable for the auxiliary diagnosis of the pre-clinical lung cancer and the biological guide treatment of the tumor, and has wide clinical application prospect and basic application prospect.
A health monitoring and diagnostic device (LIFESTREAM cholesterol meter) configured as a self-contained testing and diagnostic unit in a clam-shell type case. One side of the case includes a spring-loaded finger stick and a compartment for carrying one or more packages of disposable items including a test strip, a needle for the finger stick, and an alcohol swipe. The other half of the case includes a test strip reader, a key pad, and a liquid crystal display. The meter reads a test strip carrying a droplet of blood and receives additional diagnostic information from the patient, such as age, gender, weight, and family history of heart disease. Within minutes, the meter displays test results, including total cholesterol levels. The meter also displays additional diagnostic results, such as the patient&#39;s &#34;cardiac age&#34;, recommended weight loss, and a cardiac risk assessment. The meter also works in connection with a network-based comprehensive health analysis and reporting system. The meter writes patient data to a smartcard. This patient data typically includes patient identification information, the test results, the diagnostic information, and the diagnostic results. A computer station reads the smartcard and establishes a network connection with a health report server over the Internet. The computer then downloads the patient data to the health report server, which prepares a comprehensive health report. Within minutes, this report is transmitted back to the computer station, where it is printed out and delivered to the patient.
The invention relates to a preparation method of the derivative of memantine hydrochloride alkyl 2-sulfer 2-nitrogen. The method belongs to the technical field of synthesis of marking precursor compound for radiopharmaceutical. The invention provides a preparation method of N-[-(N-2-thiolethy)) amino acetyl]-(2- thiolethy)-3, 5-NCAM to prepare the radiopharmaceutical of &lt;99m&gt;Tc-NCAM marked by technetium which is used for image display of a brain receptor. Being approved by experiment, the NCAM meets the requirements of permeability about blood brain barrier (BBB) in the aspects such as electroneutrality, molecule size and lipid solubility (LogP). After being mixed with other adjuvant drug and frozen, the NACM is easy to produce a medicine box with good stability and a marking rate of above 95 percent. The prepared &lt;99m&gt;Tc-NCAM is tested by an animal distribution in mouse and radiation self-developing test, and the result is that the &lt;99m&gt;Tc-NCAM concentrates on the striaturn and hippocampus of the mouse. With high safety in animal test, the invention is a potential developer of the brain receptor.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a new agent using CAP11 (a 11 kDa basic antibacterial polypeptide) as active component.  &lt;P&gt;SOLUTION: The anandamide formation inhibitor comprises a dimer of peptide comprising an amino acid sequence expressed by sequence No 1, as active component. The peptide dimer comprising the amino acid sequence expressed by sequence No 1 preferably has a disulfide bonding formed between cycteine residueses of the 41th amino acid in the sequence No 1. The formation of anandamide is preferably formation of the anandamide by cells. The formation of anandamide is preferably formation of the anandamide induced by a lipopolysaccharide. The agent is usable for not only test reagents, such as medical, cytobiology etc., but also for a preventive of endotoxin shock, a deterioration preventive, an alleviation (amelioration of disease) agent, remedy, etc.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
The invention discloses wolfberry-containing health hericium erinaceus rice wine and a preparation method thereof. The wolfberry-containing health hericium erinaceus rice wine is prepared from 30-35 parts by weight of hericium erinaceus, 300-320 parts by weight of rice, 2-3 parts by weight of pine nut, 3-4 parts by weight of roasted sweet potato, 2-3 parts by weight of chicken kidney powder, 1-2 parts by weight of rose petal, 10-12 parts by weight of wolfberry juice, 1-2 parts by weight of sea-buckthorn, 1-2 parts by weight of gynostemma pentaphylla, 1-2 parts by weight of wapiti embryo, 2-3 parts by weight of scallion, 2-3 parts by weight of ginger, 2-4 parts by weight of cooking wine and a proper amount of distiller&#39;s yeast, yeast, table salt and water. The preparation method comprises chopping rose petals, immersing the chopped rose petals in a wolfberry juice, putting pine nuts into the wolfberry juice, carrying out heating boiling, and adding roasted sweet potato and chicken kidney powder into the mixture. The rose petal improves a powder delicate fragrance. The wolfberry juice improves powder health effects and has a thick fragrance and a good taste. The used traditional Chinese medicines have effects of diminishing inflammation and removing toxins, and relieving cough and removing phlegm. The hericium erinaceus is immersed in rice washing water with table salt and the rice washing water is natural alkaline water so that a hericium erinaceus bitter taste is reduced well.
&lt;P&gt;PROBLEM TO BE SOLVED: To develop a technique for controlling a mast cell (obese cell) having important roll on an in vivo defence mechanism such as inflammation and immune reaction because the mast cell has a granule rich in inflammation-inducing material, releases the granule by being activated and induces a series of in vivo defense activities but the disorderly activation is considered to be a cause of various kinds of diseases such as asthma and allergy.  &lt;P&gt;SOLUTION: The galectins-9 or -8, especially the stabilized galectins-9 or -8, or the galectin-9 inducer strongly inhibits the release of the granule from the mast cell. The mast cell stabilizer contains one selected from the galectins-9 or -8, a modified product thereof (stabilized galectins-8 and -9) and a galectin-9 inducer as an active ingredient. The agent and method for treating and/or preventing disease or disorder utilizing the stabilizing activities are also provided. Also, the anticancer technique and granular controlled release assay system are provided.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
291,018. I. G. Farbenindustrie Akt.- Ges. May 23, 1927, [Convention date]. Medicines for internal use.-Two active substances, having opposite effects on the female sexual organs, are obtained from the anterior lobe of the hypophysis by extraction with organic liquids and with aqueous solvents respectively. When an organic solvent miscible with water is used, for instance acetone, the gland is extracted first with this and the residue then extracted with water, physiological salt solution, Ringer&#39;s solution. or the like. The separate extracts are each purified in the usual manner and that obtained by the use of the organic solvent may be freed from solvent in a vacuum and again dissolved in aqueous diethylin. A known process wherein the gland is extracted with alcohol diluted with water is also referred to. In the Specification as open to inspection under Sect. 91 (3) (a) it is stated that when, using solvents immiscible with water, such as ether or ligroin, the gland may be treated simultaneously with the two solvents, and also that alcohol may be used in place of acetone. This subject-matter does not appear in the Specification as accepted.
A method and system for selecting and producing a customized cosmetic or pharmaceutical formulation is disclosed below. The system can be implemented in an Internet based system or a stand-alone version, such as a Kiosk. An improved method of custom formulation is presented which utilizes the user&#39;s preferences and profile, as well as external factors. The customized formulation can be directed to a manufacturing facility for on-demand production. Alternatively, a printout of the formulation can be provided for subsequent use at point-of-sale locations, such as a cosmetics store or a pharmacy. The custom formulation software can also be provided in conjunction with a cosmetics manufacturing kit for use in home or business application.